A Phase II Study of Weekly Versus Every 2-week Versus Every 3-week Administration of ABI-007 (Abraxane) in Combination With Bevacizumab in Women With Metastatic Breast Cancer.

Trial Profile

A Phase II Study of Weekly Versus Every 2-week Versus Every 3-week Administration of ABI-007 (Abraxane) in Combination With Bevacizumab in Women With Metastatic Breast Cancer.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 19 Mar 2012

At a glance

  • Drugs Bevacizumab; Paclitaxel
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 10 Dec 2011 Results presented at the 34th Annual San Antonio Breast Cancer Symposium.
    • 19 Apr 2011 Status changed from active, no longer recruiting to discontinued, according to ClinicalTrials.gov.
    • 03 Jun 2009 Interim results presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO-2009).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top